Inflammatory myofibroblastic tumor (IMT) · line 1 · Crizotinib monotherapy (ALK-fusion-positive inflammatory myofibroblastic tumor)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-CRIZOTINIB-IMT |
| ID | IND-IMT-ALK-CRIZOTINIB |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff |
| Diseases | DIS-IMT |
| Sources | SRC-NCCN-SARCOMA |
Notes
STUB scaffold. Auto-generated minimal indication so engine can route end-to-end. Pending Clinical Co-Lead review per CHARTER §6.1 dev-mode signoff exemption.
Used By
Algorithms
ALGO-IMT-1L- ALGO-IMT-1L